This project, which will run for three years with an investment of over 8 million, has the financial support of the Centre for Industrial Technological Development (CDTI). In addition, it aims to drive a high-tech pioneer in the world called SMRT-NNGS that once validated VHIR, will become incorporated in 2017 at the Hospital del Mar and the IMIM, VHIO, the University Hospital Vall d 'Hebron and IDIBELL.
According to recent news out of Barcelona is this equipment has been given to them by Roche for validation in infectious diseases and oncology. Once validated it will be commercialized in 2017.
The first objective of the project is the validation of the new technology, which will be held at the Vall d'Hebron Research Institute, which has a few weeks with the first pre-commercial unit NNGS-SMRT platform out of research and development facilities located in California Roche.
Published on Jul 7, 2016
Researchers from Vall d'Hebron Research Institute (VHIR) count, for a few weeks now, with the newest massive sequencing techniques. This is a new fourth-generation platform in massive DNA sequencing (also known as NNGS: Next Next Generation Sequencing), that Roche Diagnostics has decided to try for the first time in the Vall d'Hebron Barcelona Hospital Campus. The aim of the new technology is to step forward in the field of high-precision personalized medicine in virology, cancer and bacteriology, to shorten the time of diagnosis and get the most pertinent information to optimize treatments.
The new technology allows us to analyze the entire genome of the virus in a single run, with greater speed and length of reading. Dr. Rafael Esteban Mur, head of the research group and Liver Diseases Service of Vall d'Hebron, stressed that "we will be able to analyze high variability genomic systems, including viruses, bacteria and tumour cells." This, he says, "will allow us to well stratify patients and choose the most accurate treatment for each case."
The team of Dr. Esteban Mur will lead the validation of the first machine that leaves the Roche's facilities, for its expertise in the development of an application to classify the types and subtypes of hepatitis viruses, detect mixed infections, and identify the mutations of these viruses that are resistant to antiviral treatments.
Once it is validated at VHIR, in early 2017, the technology will be applied to other fields of microbiology and virology at the same Institute, and will also be transferred to other research groups of Vall d'Hebron Institute of Oncology (VHIO), the Hospital del Mar, the Institute of Biomedical Research of Bellvitge (IDIBELL), the Catalan Institute of Oncology and the Institute for AIDS Research IrsiCaixa. The CEO of Roche in Spain, Jaime Vives, explains that "the very positive experiences with these centres of biomedical research, especially with the Vall d'Hebron, have made Roche bring to Barcelona the first of its new generation platforms that is installed in the world."
These centres have formed a consortium to be divided into two main areas: the development of NNGS applications for the diagnosis of infectious agents (viruses and bacteria), the development of NNGS applications for the diagnosis of cancer. Director of VHIR, Dr. Joan Comella said that "the potential of each of the institutes and hospitals that are part of the consortium, as well as the uniqueness of the Catalan bioregion, ensure the project success."
Zacks Investment Research Upgrades Pacific Biosciences of California Inc. (PACB) to “Hold”
Posted by Scott Davis on Jul 11th, 2016 // No Comments
Pacific Biosciences of California logoPacific Biosciences of California Inc. (NASDAQ:PACB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday.
According to Zacks, “Pacific Biosciences’ full-year 2016 guidance failed to impress. In addition to the headwind related to the limited availability of Single Molecule, Real-Time (SMRT) cells for the Sequel system and lower contractual revenues, higher non-cash operating expenses will hurt bottom-line growth. We believe persistent losses and cash burn are the primary headwinds in the near term. Nevertheless, we believe growing adoption of the Sequel system will boost the top line in 2016 and beyond. Moreover, lower product development cost for the Sequel system will expand gross margin. Meanwhile, estimates have been stable lately ahead of the company’s second-quarter earnings release. Additionally, development and distribution collaborations will drive market penetration over the long haul.”
Pacific Biosciences of California (NASDAQ:PACB) traded down 0.7145% during trading on Monday, hitting $7.4762. The stock had a trading volume of 539,912 shares. Pacific Biosciences of California has a 12 month low of $3.58 and a 12 month high of $14.00. The stock has a 50 day moving average price of $8.74 and a 200-day moving average price of $9.58. The stock’s market cap is $651.69 million.
Roche Diagnostic has changed its Home page they used to have image of Roche sequencer, they have taken it down.
if we continue use short read sequencer for human genomes, we need another 15years even longer to solve some problems.